Physician profile
Ralph D Hellams
NPI 1053380352
$1,819.80
in general payments reported to CMS, 2019-2025
26 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.07 · 2020: $134 · 2021: $359 · 2022: $273 · 2023: $220 · 2024: $480 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $286.08 | 2020-2023 | Myrbetriq |
| Ucb, INC. | $168.85 | 2024 | Briviact |
| Sumitomo Pharma America, INC. | $129.45 | 2023-2024 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.83 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $106.75 | 2022 | |
| Pfizer INC. | $102.00 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $100.25 | 2021-2022 | |
| Novo Nordisk INC | $80.07 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $79.73 | 2021-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $74.25 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $67.03 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $64.38 | 2019-2020 | |
| Eisai INC. | $59.44 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $56.87 | 2020-2024 | Rexulti |
| Lundbeck LLC | $52.56 | 2021-2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.65 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $37.88 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $32.08 | 2024-2025 | Farxiga |
| Avanir Pharmaceuticals, INC. | $29.61 | 2022 | |
| Neurocrine Biosciences, INC. | $28.37 | 2025 | |
| Neurelis, INC. | $22.28 | 2023 | Valtoco |
| Janssen Pharmaceuticals, INC | $20.99 | 2019 | |
| Merck Sharp & Dohme LLC | $18.61 | 2021 | |
| Kyowa Kirin, INC. | $14.49 | 2023 | Crysvita |
| Teva Pharmaceuticals USA, INC. | $14.29 | 2023 | Austedo Xr |
| Regeneron Healthcare Solutions, INC. | $13.01 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Hellams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.